NextCure (NXTC)
(Delayed Data from NSDQ)
$1.31 USD
0.00 (0.00%)
Updated Nov 5, 2024 04:00 PM ET
After-Market: $1.31 0.00 (0.00%) 6:14 PM ET
3-Hold of 5 3
C Value B Growth C Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$1.31 USD
0.00 (0.00%)
Updated Nov 5, 2024 04:00 PM ET
After-Market: $1.31 0.00 (0.00%) 6:14 PM ET
3-Hold of 5 3
C Value B Growth C Momentum C VGM
Zacks News
Here's Why NextCure, Inc. (NXTC) Looks Ripe for Bottom Fishing
by Zacks Equity Research
NextCure, Inc. (NXTC) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
NextCure (NXTC) Down on Shelving Plans to Develop Candidate
by Zacks Equity Research
NextCure (NXTC) plans to focus on developing LNCB74 and stop the development of NC762 to conserve cash. The company's shares decline on the same.
All You Need to Know About NextCure, Inc. (NXTC) Rating Upgrade to Buy
by Zacks Equity Research
NextCure, Inc. (NXTC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
NextCure, Inc. (NXTC) Moves to Buy: Rationale Behind the Upgrade
by Zacks Equity Research
NextCure, Inc. (NXTC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
NextCure (NXTC) in Focus: Stock Moves 7.6% Higher
by Zacks Equity Research
NextCure (NXTC) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.
Will NextCure, Inc. (NXTC) Report Negative Q2 Earnings? What You Should Know
by Zacks Equity Research
NextCure, Inc. (NXTC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
NextCure Inc (NXTC) Beats Q1 Earnings and Revenue Estimates
by Zacks Equity Research
NextCure Inc (NXTC) delivered earnings and revenue surprises of 156.90% and 1621.39%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Why You Shouldn't Bet Against NextCure (NXTC) Stock
by Zacks Equity Research
NextCure (NXTC) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well